Loading patent…
AssigneeAlethia Biotherapeutics Inc.
InventorsRoy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
Estimating the term…
This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.
An antibody or antigen binding fragment capable of specific binding to a polypeptide consisting of SEQ ID NO.:48 or SEQ ID NO.:82 wherein said antibody or antigen binding fragment inhibits osteoclast differentiation or bone resorption activity of osteoclasts.
A pharmaceutical composition comprising:
An antibody or antigen binding fragment capable of specific binding to a polypeptide consisting of SEQ ID NO.:48 or SEQ ID NO.:82, wherein said antibody or antigen binding fragment is characterized with its ability to inhibit osteoclast differentiation in an in vitro assay, said assay comprising the steps of:
An antibody or antigen binding fragment which specifically binds to a polypeptide consisting of SEQ ID NO:48 or SEQ ID NO:82 and is produced by a process including a characterization step indicative of its ability to inhibit osteoclast differentiation activity or inhibit bone resorption.
Dependencies are inferred from the claim text.